A5055587157- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Single-cell and spatial transcriptomics
- Chronic Myeloid Leukemia Treatments
- Cancer Genomics and Diagnostics
- RNA Interference and Gene Delivery
- Zebrafish Biomedical Research Applications
- CRISPR and Genetic Engineering
University of Eastern Finland
2022-2025
Abstract PAX5 acts as a master regulator of B-cell proliferation and differentiation. Its germline somatic deregulation have both been implicated in the development precursor acute lymphoblastic leukemia (BCP-ALL). However, process how reduced transcriptional activity mediates progression to BCP-ALL, is still poorly understood. Here, we characterized longitudinal effects reduction on healthy, pre-leukemic BCP-ALL cells at single-cell level. Cell-surface marker analysis revealed...
Approximately 25% of children with B-cell precursor acute lymphoblastic leukemia (pB-ALL) harbor the t(12;21)(p13;q22) translocation, leading to ETV6::RUNX1 (E::R) fusion gene. This translocation occurs in utero, but disease is much less common than prevalence newborns, suggesting that secondary mutations are required for overt leukemia. The role these remains unclear and may contribute treatment resistance recurrence. We developed a zebrafish model E::R using CRISPR/Cas9 introduce human...
Background: Acute lymphoblastic leukemia (ALL) is the most common cancer in children, with about 3500 children diagnosed yearly Europe. A quarter of cases harbor ETV6-RUNX1 (E/R) fusion gene. E/R leukemias are usually classified into low risk group. However, a fraction patients still encounters disease recurrence. The increased relapse has been linked non-optimal initial therapy response as measured by minimal residual (MRD). Aims: aim this study to identify genetic differences between...